USPTO Patent US12601742B2 for Endometrial Cancer Treatment Methods
Summary
USPTO granted patent US12601742B2 to Mayo Foundation for Medical Education and Research covering methods and materials for assessing and treating endometrial cancer. The patent covers methods for identifying endometrial cancers likely to respond to particular cancer treatments by assessing combinations of mutations and expression levels, such as platinum-based therapies. The patent contains 22 claims.
What changed
USPTO granted patent US12601742B2 to Mayo Foundation for Medical Education and Research for methods and materials related to assessing and treating endometrial cancer. The patent covers cancer treatment methods involving identification of likely treatment responders by assessing combinations of mutations and expression levels, particularly for platinum-based cancer therapies. The patent was filed on May 3, 2021, under application number 17922720.
Healthcare providers and pharmaceutical companies developing cancer treatments should consider this patent when designing clinical studies or developing therapeutic protocols for endometrial cancer. The patent may affect freedom-to-operate analysis for competing therapeutic approaches in this area.
What to do next
- Monitor for updates
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods and materials for treating endometrial cancer by assessing combinations of mutations and expression levels
Grant US12601742B2 Kind: B2 Apr 14, 2026
Assignee
Mayo Foundation for Medical Education and Research
Inventors
Karl C. Podratz, Jesus Gonzalez Bosquet
Abstract
This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having endometrial cancer. For example, methods and materials for identifying endometrial cancers likely to respond to a particular cancer treatment (e.g., a platinum based cancer therapy) are provided. This document also relates to materials and methods for using one or more cancer treatments to treat a mammal (e.g., a human) identified as likely to respond to a particular cancer treatment.
CPC Classifications
G01N 33/57442 G01N 2800/52 C12Q 2600/106 C12Q 2600/156 C12Q 2600/158 C12Q 2600/16 C12Q 1/6886 A61P 35/00
Filing Date
2021-05-03
Application No.
17922720
Claims
22
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.